Birth Control Primed For Switch
This article was originally published in The Tan Sheet
Executive Summary
A new paradigm for nonprescription approvals could eliminate the risk of self-selecting a birth control drug, with some contraindications might likely not apparent, by having pharmacists provide counseling and screening or having women use a self-assessment tool with a standard algorithm.
You may also be interested in...
Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study
HRA Pharma started recruiting in April for an actual use trial, using oral contraceptives with norgestrel 0.075 mg, and expects to complete its study in April 2019, according to clinicaltrials.gov's database. Advocacy group Ibis Reproductive Health, which is working with HRA on an NDA for an OTC oral contraceptive, called the start of the study a "pivotal moment" in moving birth control drugs out of Rx-only.
Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study
HRA Pharma started recruiting in April for an actual use trial, using oral contraceptives with norgestrel 0.075 mg, and expects to complete its study in April 2019, according to clinicaltrials.gov's database. Advocacy group Ibis Reproductive Health, which is working with HRA on an NDA for an OTC oral contraceptive, called the start of the study a "pivotal moment" in moving birth control drugs out of Rx-only.